News
Future Fertility adds new partner Apricity Fertility on the heels of achieving UK regulatory approval
Future Fertility received CE Mark approval for its oocyte assessment software in August and continues to steadily grow its presence across Europe
Future Fertility has received UK regulatory approval for its AI-based oocyte assessment software, expanding UK footprint in partnership with Apricity Fertility.
Future Fertility develops AI-powered solutions that empower fertility patients and their providers with personalised insights to help optimise the fertility journey.
The company’s AI decision support software for oocyte (human egg) quality assessment has achieved UK compliance for commercial use across the UK.
Future Fertility previously received CE Mark approval in the summer of 2022. Now, this UK achievement further solidifies their commercial presence in Europe.
Its Oocyte Software is the first and only non-invasive, clinically validated tool to use artificial intelligence to analyse 2D images of oocytes and generate personalised insights about egg quality.
In today’s standard of care, fertility specialists and embryologists make judgments about egg quality based on a patient’s age group, but this doesn’t account for the variability between patients in the same age group, especially among younger patients.
Through VIOLET™ (for egg freezing patients) and MAGENTA™ (for IVF-ICSI patients), patients and providers can understand the likelihood of each retrieved egg developing to a day 5/6 embryo (eligible for blastocyst transfer), which helps to manage expectations for success and optimise treatment plans.
Future Fertility has already teamed up with leading-edge clinics to integrate their AI solutions and provide the best patient care.
As a longstanding collaborator and partner to the CARE Fertility clinic group, the technology has proven to be scientifically valid and useful to the patient experience.
As Future Fertility expands their UK footprint, they are proud to announce a new partnership with their first virtual clinic partner, Apricity.
Apricity is the UK’s first virtual fertility clinic. Their unique virtual model and mobile app has reimagined the fertility journey, enabling patients to easily navigate each step of the fertility process with at-home solutions and access to world class specialists.
Its digital solution is designed to improve the fertility experience and maximise chances of conception via a fully-customised treatment journey for patients.
Apricity partners with a selected network of clinics around the UK to deliver required in-person treatments, bringing visits to a clinic down to two per cycle rather than ten as with a traditional journey.
“The UK is a leading market in fertility care, the birthplace of the first IVF baby,” says Future Fertility CEO, Christy Prada.
“We are proud to have strong partners in the UK and look forward to partnering with Apricity to bring our products to new patient groups and clinics across the region.”
Apricity and Future Fertility’s partnership will launch as a pilot programme, kicking off this year in cooperation with IVF London.
Oocyte assessment will be conducted via the IVF London lab using Future Fertility’s software, and results will be made available to patients to discuss with their fertility specialists.
Apricity CEO, Caroline Noublanche comments: “Apricity are excited to partner with Future Fertility on this pilot, which aligns with our ‘less stress & more success’ approach.
“‘Less stress’ as giving our patients a greater level of transparency on their oocytes and chances right after egg collection and ‘better success’ as complementing Apricity’s own AI and the amazing embryology team at IVF London to make the best informed choices and ultimately improve the chances of conception.”
For more info, visit futurefertility.com.
Small bowel microbiome differences between women and men may help explain why some conditions are more common in women, a study suggests.
The small bowel microbiome is the community of microorganisms living in this part of the digestive tract, where they play vital roles in immune function, metabolism and hormonal regulation.
Researchers found differences between women and men in the composition and organisation of these microbial communities. One bacterial community containing Granulicatella was found only in women.
The study was conducted by investigators at Cedars-Sinai Health Sciences University.
Ruchi Mathur, director of clinical research and clinical operations for the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai and corresponding author of the study, said: “One intriguing finding was a bacterial community containing Granulicatella, which we found only in women.
“Bacteria in this community appear at increased levels in women with polyendocrine metabolic ovarian syndrome, formerly known as polycystic ovary syndrome.”
The researchers also identified differences between women and men in how microbes in the small bowel produce fructans, complex carbohydrates known to trigger digestive symptoms in irritable bowel syndrome (IBS).
IBS is far more common in women than men.
Mathur, who is also a professor of medicine, said: “Our findings show that biological sex is a critical variable in the small bowel microbiome.
“We must consider it as we move toward more personalised approaches to understanding and treating disease.”
An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.
The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.
Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.
Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.
Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.
Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.
Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.
Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.
Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.
“So much remains unknown about the impact of this type of surgery on women who are planning to have children.
“This raises the question of when the ideal time after surgery is to conceive.”
Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.
The researchers said 17 women had healthy pregnancies following surgery.
Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.
Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.
“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.
“By reducing this, what we have seen is that it can lead to improvements without the need for medication.
“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”
Diagnosis2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur7 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Mental health1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Menopause5 days agoMenopause hormone treatment may ease brain fog, study suggests